Background NVX-CoV2373 is a recombinant severe acute respiratory coronavirus 2 (rSARS-
CoV-2) nanoparticle vaccine composed of trimeric full-length SARS-CoV-2 spike …

Background Early clinical data from studies of the NVX-CoV2373 vaccine (Novavax), a
recombinant nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2 …

Background NVX-CoV2373 is a recombinant severe acute respiratory syndrome
coronavirus 2 (rSARS-CoV-2) nanoparticle vaccine composed of trimeric full-length SARS …

Background NVX-CoV2373 is an adjuvanted, recombinant spike protein nanoparticle
vaccine that was shown to have clinical efficacy for the prevention of coronavirus disease …

Summary Background Emerging SARS-CoV-2 variants and evidence of waning vaccine
efficacy present substantial obstacles towards controlling the COVID-19 pandemic. Booster …

Background The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) variants threatens progress toward control of the coronavirus disease 2019 (Covid …

Background There is a paucity of data on COVID-19 vaccines in people living with HIV-1,
who could be at increased risk of severe illness and death from COVID-19. We evaluated …

Background The recombinant protein-based vaccine, NVX-CoV2373, demonstrated 89.7%
efficacy against coronavirus disease 2019 (COVID-19) in a phase 3, randomized, observer …

Background Vaccines are urgently needed to prevent the global spread of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). We assessed the safety and …

Importance Greater than 20% of cases and 0.4% of deaths from COVID-19 occur in children.
Following demonstration of the safety and efficacy of the adjuvanted, recombinant spike …